[go: up one dir, main page]

WO1999003364A1 - Composition nourrissante pour sujet en etat de stress - Google Patents

Composition nourrissante pour sujet en etat de stress Download PDF

Info

Publication number
WO1999003364A1
WO1999003364A1 PCT/IB1998/001056 IB9801056W WO9903364A1 WO 1999003364 A1 WO1999003364 A1 WO 1999003364A1 IB 9801056 W IB9801056 W IB 9801056W WO 9903364 A1 WO9903364 A1 WO 9903364A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
carnitine
stress
alkanoyl
ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/001056
Other languages
English (en)
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority to CA002296540A priority Critical patent/CA2296540A1/fr
Priority to HU0004526A priority patent/HUP0004526A3/hu
Priority to AU79277/98A priority patent/AU727448B2/en
Priority to PL98338079A priority patent/PL338079A1/xx
Priority to JP2000502680A priority patent/JP2001510026A/ja
Priority to SK1819-99A priority patent/SK181999A3/sk
Priority to EP98929576A priority patent/EP0999757A1/fr
Priority to KR1020007000253A priority patent/KR20010021694A/ko
Publication of WO1999003364A1 publication Critical patent/WO1999003364A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a nutritional composition or medical food for subjects in a debilitated state as a result of stress.
  • This syndrome afflicts all social classes, but mainly affects people involved in the production cycle, who often, as a result, are subject to greater competitive stress stimuli both in the work environment and in the conduct of their social relations.
  • stress syndrome is not a debilitating "disease” to the extent that it makes people bed-ridden, but it is certainly a frequent cause of people taking days off work. Since it afflicts a substantial number of individuals, it causes a considerable burden of economic damage to the entire community during the working year. Stress syndrome, which in the past was improperly called "nervous breakdown', is characterised, in the absence of active disease, by concomitant states of malaise, such as a lack of strength, debilitation, states of mental and physical fatigue, lack of concentration and attention, and lack of sexual vigour and libido.
  • Benzodiazepines are used to alleviate symptoms such as anxiety or irritability, but present the drawback of causing addiction as well as further depressing libido and sexual vigour, thus triggering a mechanism in male subjects of reproductive age which itself proves to be a cause of additional malaise.
  • L-carnitine when used for the treatment of patients undergoing regular dialysis treatment, also induces recovery of normal sexual function in such patients (De Felice SL, Lyons P, Gaf ⁇ ar MC, Sheridan MJ, Dial-Transplant, 1996, vol/iss/pg. 25/6 368-373).
  • Ginseng has been used in Chinese medicine for more than 2000 years for the treatment of sexual impotence and for other diseases. Also well known is the activity of yohimbine in improving sexual function; see, for example, "Clinical Studies in Impotence”: K Reid et al., Lancet 2, 421-423 (1987). Guarana is used by Brazilian indigenous populations for the preparation of a stimulating beverage (Pharmacognosy, Edward P Claus, Varro E Tyler, Lynn R Brady, 6th edition pp. 292-293). Damiana has also long been known to be endowed, according to popular belief, with stimulant activity (J Psychoactive Drugs 16 (3): 267-268, 1984).
  • the purpose of the present invention is now to provide a therapeutic medical food suitable for alleviating and treating states of malaise caused by stress and for promoting sexual vigour.
  • the therapeutic medical food of the invention comprises the following compounds in combination:
  • ginseng natural extract of Panax ginseng
  • yohimbine natural extract of Corynanthe yohimbe
  • damiana natural extract of Turnera diffusa, ⁇ ar. aphrodisiaca
  • the alkanoyl L-carnitine should preferably be chosen from among the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its pharmacologically acceptable salts.
  • pharmacologically acceptable salt of L- camitine or of an alkanoyl L-carnitine is any salt of these with an acid which does not give rise to unwanted toxic or side effects.
  • acids are well known to pharmacologists and experts in pharmacy.
  • Non-limiting examples of pharmacologically acceptable salts of L-carnitine or of the alkanoyl L-carnitines are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.
  • the components of the combination according to the invention exhibit an unexpected potent synergistic effect which brings about an improvement in physical performance and in the mental and physical condition of patients suffering from stress syndrome.
  • Very important and surprising is the synergistic effect shown by the combination of ginseng, yohimbine and L-carnitine in restoring sexual vigour and libido,
  • the effect of the combination is, in fact, distinctly superior to the sum of the effects of the individual components.
  • L-carnitine and lecithin of soya favour the metabolisation of fatty acids, exerting a hypolipaemic effect on the body, which, though having no direct repercussions in terms of improving stress syndrome, is aimed at enhancing the individual's general state of health.
  • the weight-to-weight ratio of L-carnitine or of an alkanoyl L- carnitine to ginseng, yohimbine, guarana and damiana may vary over a broad range, This ratio should preferably range from 1:0.1:0.0025:0.1:0.1 to 1 : 10:0.25: 100:100.
  • One preferred ratio is
  • composition according to the invention may additionally contain vitamins, metals, coenzymes, inorganic or organic antioxidants or their precursors.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition nourrissante (aliment fonctionnel) pour sujets se trouvant dans un état d'affaiblissement consécutif au stress. Ladite composition comprend une combinaison: (a) de L-carnitine ou de L-carnitine d'alcanoyle ou d'un de leurs sels pharmacologiquement acceptables; (b) d'un mélange d'extraits végétaux naturels (ex: yohimbine et guarana); (c) de lécithine de soja; et (d) d'acide malique.
PCT/IB1998/001056 1997-07-16 1998-07-10 Composition nourrissante pour sujet en etat de stress Ceased WO1999003364A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002296540A CA2296540A1 (fr) 1997-07-16 1998-07-10 Composition nourrissante pour sujet en etat de stress
HU0004526A HUP0004526A3 (en) 1997-07-16 1998-07-10 Nutritional composition for subjects under stress
AU79277/98A AU727448B2 (en) 1997-07-16 1998-07-10 Nutritional composition for subjects under stress
PL98338079A PL338079A1 (en) 1997-07-16 1998-07-10 Nourishing composition for persons under a stress
JP2000502680A JP2001510026A (ja) 1997-07-16 1998-07-10 ストレス下にある患者のための栄養組成物
SK1819-99A SK181999A3 (en) 1997-07-16 1998-07-10 Nutritional composition for subjects under stress
EP98929576A EP0999757A1 (fr) 1997-07-16 1998-07-10 Composition nourrissante pour sujet en etat de stress
KR1020007000253A KR20010021694A (ko) 1997-07-16 1998-07-10 스트레스 받는 자에 유용한 영양 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM97A000435 1997-07-16
IT97RM000435A IT1293539B1 (it) 1997-07-16 1997-07-16 Composizione nutritiva per soggetti in stato di debilitazione causato da stress

Publications (1)

Publication Number Publication Date
WO1999003364A1 true WO1999003364A1 (fr) 1999-01-28

Family

ID=11405180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001056 Ceased WO1999003364A1 (fr) 1997-07-16 1998-07-10 Composition nourrissante pour sujet en etat de stress

Country Status (11)

Country Link
EP (1) EP0999757A1 (fr)
JP (1) JP2001510026A (fr)
KR (1) KR20010021694A (fr)
CN (1) CN1263439A (fr)
AU (1) AU727448B2 (fr)
CA (1) CA2296540A1 (fr)
HU (1) HUP0004526A3 (fr)
IT (1) IT1293539B1 (fr)
PL (1) PL338079A1 (fr)
SK (1) SK181999A3 (fr)
WO (1) WO1999003364A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022263A1 (fr) * 2001-09-07 2003-03-20 Ivars Kalvinsh Composition pharmaceutique comprenant de la gamma-butyrobetaine destinee a stimuler l'activite et la puissance sexuelles
AT410277B (de) * 2001-02-22 2003-03-25 Peter Dr Frigo Getränk
WO2003047563A1 (fr) * 2001-12-04 2003-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Utilisation d'alcanoyl l-carnitine pour traiter le dysfonctionnement erectile
DE102005053241A1 (de) * 2005-11-08 2007-05-16 Schwabe Willmar Gmbh & Co Extrakte aus der Rinde von Corynanthe-Arten und deren Verwendung sowie diese Extrakte enthaltende Arzneimittel, diätetische Lebensmittel und pharmazeutische Zubereitungen
JP2016123324A (ja) * 2014-12-26 2016-07-11 花王株式会社 固形状組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2355192C2 (ru) * 2002-09-28 2009-05-20 Фарматон С.А. Композиция, содержащая экстракты panax ginseng и paullinia cupana
CN101868243A (zh) * 2007-11-21 2010-10-20 客乐谐制药株式会社 芳香酶抑制剂
CN113116898A (zh) * 2021-04-20 2021-07-16 北京天玺宝科技有限公司 一种具有减肥功能的包含左卡尼汀或乙酰左卡尼汀和育亨宾的组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
WO1997042928A1 (fr) * 1996-05-14 1997-11-20 Lvmh Recherche Composition topique amincissante
US5744187A (en) * 1996-12-16 1998-04-28 Gaynor; Mitchel L. Nutritional powder composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
WO1997042928A1 (fr) * 1996-05-14 1997-11-20 Lvmh Recherche Composition topique amincissante
US5744187A (en) * 1996-12-16 1998-04-28 Gaynor; Mitchel L. Nutritional powder composition

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410277B (de) * 2001-02-22 2003-03-25 Peter Dr Frigo Getränk
WO2003022263A1 (fr) * 2001-09-07 2003-03-20 Ivars Kalvinsh Composition pharmaceutique comprenant de la gamma-butyrobetaine destinee a stimuler l'activite et la puissance sexuelles
WO2003047563A1 (fr) * 2001-12-04 2003-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Utilisation d'alcanoyl l-carnitine pour traiter le dysfonctionnement erectile
KR100907938B1 (ko) * 2001-12-04 2009-07-16 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 발기 기능장애의 치료를 위한 알카노일 ｌ-카르니틴의 용도
US8343979B2 (en) 2001-12-04 2013-01-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of alkanoyl L-carnitine for the treatment of erectile dysfunction
DE102005053241A1 (de) * 2005-11-08 2007-05-16 Schwabe Willmar Gmbh & Co Extrakte aus der Rinde von Corynanthe-Arten und deren Verwendung sowie diese Extrakte enthaltende Arzneimittel, diätetische Lebensmittel und pharmazeutische Zubereitungen
JP2016123324A (ja) * 2014-12-26 2016-07-11 花王株式会社 固形状組成物

Also Published As

Publication number Publication date
ITRM970435A0 (fr) 1997-07-16
HUP0004526A2 (hu) 2001-04-28
JP2001510026A (ja) 2001-07-31
HUP0004526A3 (en) 2001-11-28
SK181999A3 (en) 2000-10-09
CA2296540A1 (fr) 1999-01-28
AU7927798A (en) 1999-02-10
PL338079A1 (en) 2000-09-25
ITRM970435A1 (it) 1999-01-16
CN1263439A (zh) 2000-08-16
AU727448B2 (en) 2000-12-14
IT1293539B1 (it) 1999-03-01
KR20010021694A (ko) 2001-03-15
EP0999757A1 (fr) 2000-05-17

Similar Documents

Publication Publication Date Title
US6831103B1 (en) Composition comprising theanine
KR100680121B1 (ko) (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제
GB2596849A (en) Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual
JP7461066B2 (ja) スポーツ上の動作を強化するための組成物
US20090011048A1 (en) Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
US7674482B2 (en) Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
KR100481188B1 (ko) 글루타민산염관련질환치료용알카노일-l-카르니틴의용도
JP5275251B2 (ja) 肝臓疾患を予防及び処置するための組合せ薬草の抽出物を含む組成物
US20060099239A1 (en) Dietary supplement for promoting removal of heavy metals from the body
AU727448B2 (en) Nutritional composition for subjects under stress
GB2282967A (en) Compositions containing fructose and plant extracts
US20040213829A1 (en) Dietary supplement
KR20050033505A (ko) 주의력 결핍 증후군 치료에 있어서 포스파티딜세린의 사용
JP2007500755A (ja) 月経前症候群の症状を抑える方法
US20030194453A1 (en) Dietary supplement
WO2002078616A2 (fr) Procede d'accroissement du niveau de serotonine d'un individu par administration d'une composition comprenant de l'acide (-)-hydroxycitrique, et compositions associees
AU2002305132A1 (en) Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
MXPA00000442A (en) Nutritional composition for subjects under stress
CZ200088A3 (cs) Nutriční přípravek pro stresované subjekty
KR20090024215A (ko) 인간의 성적 활동성을 향상시키기 위한 수단과 방법들
EP1383579A2 (fr) Composition pour la prevention ou le traitement de troubles d'apprentissage chez les enfants souffrant de trouble d'hyperactivite avec deficit de l'attention
KR20120055159A (ko) 감국 추출물을 포함하는 불면 증상의 예방 및 개선용 조성물과 그의 제조방법
HUP0202079A2 (en) Cardioactive composition comprising l-carnitine and its derivatives and crataegus extracts
KR20230106783A (ko) 초임계유체 추출법을 이용한 혼합추출물을 유효성분으로 함유하는 남성 성기능 개선용 조성물
JP2008019190A (ja) 天然物由来の意欲改善剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98807193.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 181999

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1998929576

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 79277/98

Country of ref document: AU

Ref document number: 501965

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09462167

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020007000253

Country of ref document: KR

Ref document number: PV2000-88

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/000442

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2296540

Country of ref document: CA

Ref document number: 2296540

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1998929576

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-88

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007000253

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 79277/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998929576

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: PV2000-88

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020007000253

Country of ref document: KR